The primary role of silicone
With the use of silicone gel, there’s an easy and convenient way to improve scars without the need for going through painful invasive procedures. Silicone gel sheets have been used successfully for almost 30 years in scar management and have been recommended as first line therapy in the treatment of a wide range of scars, as well as for the prevention of abnormal scars.1
Silicone therapy has a primary role in scar management. Silicones have proven to be a safe and effective treatment for many types of scars. “A silicone-based product may represent the easiest way to achieve an effective level of occlusion in an inexpensive, non-irritating manner.”2
Strataderm does not show the same irritation level that is associated with traditional silicone gel sheeting.
Silicone gel sheeting was first used in 1982 by a group of clinicians who in an effort to apply uniform pressure to burns/scars in all locations trialled silicone gel sheeting in combination for splints and compression bandages.3 Since that time it has become well established in the medical field that silicone is a safe and effective treatment for scars. In 1985 a study was published with results that indicated that silicone fluid was not permeable through the epidermis/dermis but is an inert, idle fluid4 and in recent years further research has concluded that silicone gel applied from a tube is as effective as silicone gel sheeting in the management of abnormal scarring.2
Strataderm is not only considered a first line treatment for scars but it is also recommended for use in conjunction with other therapy options, such as corticosteroid injections and pressure garments.
An international advisory panel on scar management in 2002 published clinical recommendations on scar management, based on a qualitative overview of 300 published references and expert consensus on best practices. Silicone gel sheeting was stated as first line therapy for the prevention of scarring and first line treatment for the initial management of scarring, in addition to the recommended management modality with adjunct therapies for secondary management.1 These clinical recommendations to date have not been superseded.
1. Mustoe TA et al. Plast Reconstr Surg 2002; 110:560–571
2. Mustoe TA. Aesth Plast Surg 2008; 32:82-92
3. Perkins, K et al. Burns 1982; 9:201
4. Quinn KJ et al. Burns 1985; 12(2):102-108